Novel approach to pediatric anti-nausea: formulating & evaluating ondansetron-infused chocolate
Abstract
Ondansetron is a widely used anti-emetic for managing nausea and vomiting caused by chemotherapy, gastroenteritis, motion sickness, and morning sickness. Traditional formulations include dispersible tablets, syrups, and injections, but these can be challenging for pediatric patients due to the bitter taste of ondansetron. To enhance palatability and patient compliance, we propose the development of a novel dosage form: ondansetron-infused chocolate. This innovative approach leverages chocolate’s natural appeal to pediatric patients, effectively masking the drug’s bitterness. By utilizing a chocolate base, we aim to improve the acceptability of ondansetron, thereby ensuring better adherence to treatment regimens. This chocolate drug delivery system represents a versatile and child-friendly technology, potentially transforming how pediatric anti-emetic therapy is administered.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.